Value proposition

Tackling metabolic disorders with non-coding RNAs


Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease.

The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.

Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.